PRADER-WILLI AND ANGELMAN SYNDROMES IN THE GREEK POPULATION: A CLINICAL AND MOLECULAR STUDY
Salavoura K*, Sofocleous C, Mavrou A, Kalaitzidaki M, Frysira H, Kolialexi A, Zafiriou D, Yapijakis C, Metaxotou E
*Corresponding Author: : Katerina Salavoura, MD, PhD, Department of Immunology and Histocompatibility, “Aghia Sophia” Children’s Hospital, Thivon and Papadiamantopoulou, Athens, Greece; Tel.: +30-210-7467766; Fax: +30-210-7757401; E-mail: Salavoura_Katerina@hotmail.com
page: 27

DISCUSSION

Prader Willi syndrome often has a rather confusing clinical presentation and many referrals do not fulfill the diagnostic criteria. Identification of appropriate patients for testing remains a challenge for clinicians because many features of the disorder are not specific, while others are subtle or evolve over time [12]. In the present series only 35% of the referred PWS cases had typical presenta­tion of the syndrome, while the remaining had obesity, hypotonia or mental retardation of other etiology. This is in concordance with previous reports that PWS is often inaccurately suspected in obese and mentally retarded patients [12]. In the present study, 30% of newborns with hypotonia were shown to have PWS, while the rest either developed various neurological or metabolic diseases or were normal. Molecular alterations were also identified in 15% of the non typical PWS cases. This is comparable with the 16.7% frequency reported in the literature [12] and supports the idea that revision of the criteria for PWS according to age may be warranted [12]. Most of our AS patients (56%) had a characteristic behavioral phenotype and facial features [13].

In agreement with previous reports, this study indi­cates that molecular abnormalities in PWS and AS are in most cases de novo deletions [2]. In general, smaller dele­tions were detected in PWS (Figs. 1 and 2). Non typical presentation without obesity and short stature was ob­served in one patient with PWS who had a deletion inside the critical region. The other six patients with molecular findings and non typical presentation were younger than 3 years old, and it is possible that they had not as yet devel­oped the full phenotype. In all AS patients with detected deletions, the deletion included the region between the D15S11 and D15S10 loci, where the UBE3A gene has been mapped [13]. Six out of 10 patients with deletion of the GABRb3 locus presented with spasms. The GABAA (g-aminobutyric acid) receptor b3 subunit is one of the major inhibitory neurotransmitters in the mammalian brain, and both in vivo and in vitro studies indicate that it is involved in the suppression of seizure activity [14].

Deletions near the D15S113 marker with normal bi­parental inheritance of the other markers were detected in four out of 28 PWS patients. The clinical presentation of PWS in 54 and 39 patients was non typical with mild behavioral problems, learning difficulties and insignificant obesity or short stature. It has been reported that some times an unamplified allele in the D15S113 locus may be misinterpreted as a small deletion. In our cases, however, heterozygosity in both parents excluded the possibility of a “null” allele [15].

The incidence of PWS and AS among twins is very rare, although there are only a few relevant reports in the literature [16-18]. In our series there was a pair of identi­cal twin PWS boys with a deletion of the paternal alleles in the 15q11-13 region, who had neonatal hypotonia, obe­sity after the fifth year and were developmentally delayed. There was also a pair of identical twin girls with AS who were born after in vitro fertilization (IVF) and were both severely retarded, with spasms and absence of speech. Both of them had a deletion of the maternal alleles in the 15q11-13 region. Increased maternal age is often the rea­son for referral for IVF, as was the case in our AS twins, and there is a positive relationship between maternal age and non-disjunction [19]. According to the literature, non-disjunction is also increased in experimental models in IVF due to in vitro conditions. After chromosome 21, chromosome 15 is the most commonly involved chromo­some in this type of aneuploidy [19].

Clinical evaluation of patients referred for investiga­tion of PWS and AS should always be performed by a specialist to classify patients as typical or non typical. Molecular investigation using DNRP or methylation tests would be necessary for all patients. Although only few patients had cytogenetic findings, it is worthwhile to per­form a karyotype analysis in all patients, since the detec­tion of possible chromosomal aberrations may be impor­tant in family counseling. In uninformative patients FISH analysis could detect deletions in some cases.


In conclusion, in our series diagnosis was confirmed by molecular findings detected in 70% of typical PWS cases and 56% of typical AS cases. Further investigation of remaining cases using additional techniques is under way [20-22].




Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006